Pfizer Inc. EBITDA Margin for the Trailing 12 Months (TTM) ending March 29, 2025: 27.59%

Pfizer Inc. EBITDA Margin is 27.59% for the Trailing 12 Months (TTM) ending March 29, 2025, a 104.60% change year over year. EBITDA Ratio is the proportion of Earnings Before Interest, Taxes, Depreciation, and Amortization to total revenue, assessing a company's operational profitability before non-operating expenses and non-cash charges.
  • Pfizer Inc. EBITDA Margin for the Trailing 12 Months (TTM) ending March 31, 2024 was 13.49%, a -67.48% change year over year.
  • Pfizer Inc. EBITDA Margin for the Trailing 12 Months (TTM) ending April 02, 2023 was 41.47%, a 12.56% change year over year.
  • Pfizer Inc. EBITDA Margin for the Trailing 12 Months (TTM) ending April 03, 2022 was 36.84%, a 30.64% change year over year.
  • Pfizer Inc. EBITDA Margin for the Trailing 12 Months (TTM) ending April 04, 2021 was 28.20%, a -39.04% change year over year.
Key Data
Date EBITDA Margin Net Income Margin EBT Margin Operating Income Margin